🚀 VC round data is live in beta, check it out!
Mineralys Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mineralys Therapeutics and similar public comparables like Immunome, Nanjing King-Friend, Hepalink, Disc Medicine and more.
Mineralys Therapeutics Overview
About Mineralys Therapeutics
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Founded
2019
HQ
Employees
51
Website
Sectors
Financials (LTM)
EV
$2B
Mineralys Therapeutics Financials
Mineralys Therapeutics reported last 12-month revenue of — and negative EBITDA of ($165M).
In the same LTM period, Mineralys Therapeutics generated — in gross profit, ($165M) in EBITDA losses, and had net loss of ($159M).
Revenue (LTM)
Mineralys Therapeutics P&L
In the most recent fiscal year, Mineralys Therapeutics reported revenue of — and EBITDA of ($161M).
Mineralys Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($165M) | XXX | ($161M) | XXX | XXX | XXX |
| Net Profit | ($159M) | XXX | ($155M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mineralys Therapeutics Stock Performance
Mineralys Therapeutics has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Mineralys Therapeutics' stock price is $29.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-1.95 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMineralys Therapeutics Valuation Multiples
Mineralys Therapeutics trades at (10.5x) EV/EBITDA.
EV / Revenue (LTM)
Mineralys Therapeutics Financial Valuation Multiples
As of March 21, 2026, Mineralys Therapeutics has market cap of $2B and EV of $2B.
Equity research analysts estimate Mineralys Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mineralys Therapeutics has a P/E ratio of (14.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/EBITDA | (10.5x) | XXX | (10.7x) | XXX | XXX | XXX |
| EV/EBIT | (10.0x) | XXX | (10.3x) | XXX | XXX | XXX |
| P/E | (14.6x) | XXX | (15.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (12.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mineralys Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mineralys Therapeutics Margins & Growth Rates
Mineralys Therapeutics' revenue in the last fiscal year grew by —.
Mineralys Therapeutics' revenue per employee in the last FY averaged $0.0M.
Mineralys Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | (1%) | XXX | 11% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mineralys Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Immunome | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanjing King-Friend | XXX | XXX | XXX | XXX | XXX | XXX |
| Hepalink | XXX | XXX | XXX | XXX | XXX | XXX |
| Disc Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Jafron Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mineralys Therapeutics M&A Activity
Mineralys Therapeutics acquired XXX companies to date.
Last acquisition by Mineralys Therapeutics was on XXXXXXXX, XXXXX. Mineralys Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mineralys Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMineralys Therapeutics Investment Activity
Mineralys Therapeutics invested in XXX companies to date.
Mineralys Therapeutics made its latest investment on XXXXXXXX, XXXXX. Mineralys Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mineralys Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mineralys Therapeutics
| When was Mineralys Therapeutics founded? | Mineralys Therapeutics was founded in 2019. |
| Where is Mineralys Therapeutics headquartered? | Mineralys Therapeutics is headquartered in United States. |
| How many employees does Mineralys Therapeutics have? | As of today, Mineralys Therapeutics has over 51 employees. |
| Who is the CEO of Mineralys Therapeutics? | Mineralys Therapeutics' CEO is Jon Congleton. |
| Is Mineralys Therapeutics publicly listed? | Yes, Mineralys Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Mineralys Therapeutics? | Mineralys Therapeutics trades under MLYS ticker. |
| When did Mineralys Therapeutics go public? | Mineralys Therapeutics went public in 2023. |
| Who are competitors of Mineralys Therapeutics? | Mineralys Therapeutics main competitors are Immunome, Nanjing King-Friend, Hepalink, Disc Medicine. |
| What is the current market cap of Mineralys Therapeutics? | Mineralys Therapeutics' current market cap is $2B. |
| Is Mineralys Therapeutics profitable? | No, Mineralys Therapeutics is not profitable. |
| What is the current EBITDA of Mineralys Therapeutics? | Mineralys Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Mineralys Therapeutics? | Current EBITDA multiple of Mineralys Therapeutics is (10.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.